Advertisement

Advertisement

Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
Posted: 10/21/2022 | By: Larry Rosenberg, PhD

Question 1 of 5

Radium-223 dichloride (Ra-223) is currently approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and:

Correct

Next Question  

Explanation

Answer: C. Ra-223 is currently approved for treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. It is not approved for patients with visceral metastases or those without bone metastases. Lutetium-177–labeled PSMA-617 (LuPSMA), not Ra-223, is approved for treatment of PSMA-positive mCRPC.